Skip to main content

Here’s why the FDA may approve a Covid-19 vaccine before the November elections, according to Jefferies’ biotech-research team

If true, any approval may not actually benefit a vaccine company, but instead other parts of the stock market.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.